07:00 , Apr 11, 2013 |  BC Innovations  |  Cover Story

RET, set, go

Just 15 months after Ret proto-oncogene fusions were first identified in 1%-2% of non-small cell lung cancer cases, early data from a Phase II trial of Exelixis Inc. 's Cometriq cabozantinib suggest that blocking the...
07:00 , Aug 15, 1994 |  BC Week In Review  |  Company News

Oclassen Pharmaceuticals Inc., Prizm deal

The companies also agreed to form an additional joint venture in the future to develop diagnostic kits that to detect specific FGF receptors in blood or urine that could screen for patients at risk of...